This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million

HighVista Strategies sold 69,092 shares of Structure Therapeutics (worth $4.73 million) in Q1 2026, reducing its stake to 1.65% of AUM. Despite the fund's partial exit, Structure Therapeutics shares have surged 60% over the past year as the company advances its oral obesity drug candidate aleniglipron toward Phase 3 trials, with recent Phase 2 data showing 16.3% placebo-adjusted weight loss and positive FDA feedback.

05/17/2026, 2:22 PM • The Motley Fool

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics announced positive Phase 2 data for aleniglipron, an oral GLP-1 receptor agonist, showing placebo-adjusted weight loss of 16.3% at 180 mg and 16.0% at 240 mg at 44 weeks—the highest efficacy among oral GLP-1 receptor agonists with comparable results to injectable alternatives. The drug demonstrated improved tolerability with a lower 2.5 mg starting dose, with low discontinuation rates due to adverse events. Phase 3 initiation is planned for the second half of 2026 following an FDA End-of-Phase 2 meeting.

03/16/2026, 7:00 AM • GlobeNewswire

PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race

PatentVest released an analysis of 1,200+ patent documents across 50 oral small-molecule GLP-1 programs, revealing dramatic disparities in patent defensibility among competitors. With injectable GLP-1s reaching only 5% of eligible patients and clinical efficacy converging around 12-16% weight loss, long-term market dominance will depend on patent portfolio strength rather than clinical performance alone. Major patent cliffs for semaglutide (2031) and tirzepatide (2036) will determine which assets become franchises versus facing generic competition.

02/26/2026, 1:35 PM • GlobeNewswire

Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It

Structure Therapeutics CEO Ray Stevens outlined the company's strategy to compete in the crowded weight-loss drug market at the JPMorgan Healthcare Conference. The company plans to advance its daily oral GLP-1 candidate, aleniglipron, into Phase 3 trials. Phase 2 data showed 11% body weight loss at 36 weeks (adjusted for placebo), with higher doses achieving up to 15.3% loss. Stevens highlighted four competitive advantages: efficacy, absence of drug-related liver injuries, cost-effective manufacturing as a small-molecule pill, and potential for combination therapy. He also warned about the risks posed by unapproved alternatives in the market.

01/23/2026, 9:18 AM • Benzinga

A 10% Owner Of Structure Therapeutics Shed Shares

FMR LLC, a Johnson family-controlled company and 10% owner of Structure Therapeutics, sold 52,356 shares worth approximately $3.8 million on December 8, 2025. Despite this insider sale, the clinical-stage biopharmaceutical company's stock has surged 212.55% over the past year, with continued momentum in 2026. The company recently closed a $748 million public offering and is developing a competitive weight loss pill.

01/13/2026, 2:33 PM • The Motley Fool

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Structure Therapeutics has priced a public offering of 8,461,538 American depositary shares at $65.00 per share and pre-funded warrants to purchase 1,538,462 ADSs, expecting to raise approximately $650 million.

12/09/2025, 11:15 PM • GlobeNewswire

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Structure Therapeutics plans to release topline data from its ACCESS clinical program for aleniglipron, an oral small molecule GLP-1 receptor agonist for obesity treatment, on December 8, 2025.

12/07/2025, 6:20 PM • GlobeNewswire

This Under-the-Radar Healthcare Stock Could Soar in 2026

Structure Therapeutics is developing an oral weight-management drug called aleniglipron, targeting the hot obesity treatment market. The company's success depends on strong clinical trial results, with potential for significant stock price movement based on its phase 2 study outcomes.

09/12/2025, 8:15 AM • The Motley Fool

This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors

Eli Lilly's oral GLP-1 drug orforglipron underperformed in weight loss trials, potentially creating opportunities for competitors like Novo Nordisk in the emerging oral weight management medication market.

08/17/2025, 7:15 AM • The Motley Fool

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Structure Therapeutics, a clinical-stage biopharmaceutical company, announced two late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions. The presentations will include preclinical data for their oral small molecule amylin agonist, ACCG-2671, and their oral small molecule GLP-1 receptor agonist, GSBR-5595.

06/20/2025, 7:30 PM • GlobeNewswire